Plenty of fund managers are telling us it's a tough time to be a value investor. Is it time to look at things differently?
One of the world's best investors thinks the stock he knows best is undervalued.
Halloween might be over but senior analyst James Greenhalgh is feeling the sugar rush of better buying opportunities ahead.
Few sectors have as many disaster stories as biotechnology. Here's why you should steer clear.
Blackmores' negligible research spending and industry-leading marketing budget show where its priorities lie. It's time to lift the lid.
If management provides earnings guidance, then surely the numbers are crystal clear? Here are four problems from 2018 which show why earnings guidance must be treated with caution.
Medical cannabis companies are the next big thing, right? Here's why you should steer clear.
Some stocks are so risky that valuing them becomes impossible. Here are three to avoid.
As John Cleese put it, 'He who laughs most, learns best'.
Two companies dominate the betting industry and recent regulatory changes could make it a duopoly.
Cochlear demonstrated these six characteristics when we upgraded the stock to Buy in 2004. Look for them if you want to buy a wonderful business at a fair price.
BlueScope Steel's stock has risen more than 900% since hitting bottom in July 2012. Here's why I don't care I missed it, and why you shouldn't either.